- Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Journal of medicinal chemistry (2009-07-28)
Patrick R Verhoest, Douglas S Chapin, Michael Corman, Kari Fonseca, John F Harms, Xinjun Hou, Eric S Marr, Frank S Menniti, Frederick Nelson, Rebecca O'Connor, Jayvardhan Pandit, Caroline Proulx-Lafrance, Anne W Schmidt, Christopher J Schmidt, Judith A Suiciak, Spiros Liras
PMID19630403
RESUMEN
By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.
MATERIALES
Referencia del producto
Marca
Descripción del producto